Results 51 to 60 of about 1,087 (181)
Abstract Focal epilepsy constitutes 60–70% of epilepsy, and up to half of patients do not achieve seizure freedom with their first antiseizure medication (ASM). When the first ASM fails, evidence guiding whether to switch or add‐on another ASM and which ASMs to use is limited. This review synthesized evidence from randomized controlled trials (RCTs) on
Isaac J. Egesa +7 more
wiley +1 more source
Clinical trial results have demonstrated that adjunctive cenobamate (CNB) substantially decreases seizure frequency in adults with uncontrolled focal onset seizures with an acceptable and well-identified safety profile.
Serratosa, José M. +6 more
core +1 more source
Cenobamate in refractory epilepsy: Overview of treatment options and practical considerations
Management of drug resistant epilepsy (DRE) represents a challenge to the treating clinician. This manuscript addresses DRE and provides an overview of treatment options, medical, surgical, and dietary.
Bettina Schmitz +5 more
doaj +1 more source
The effect of anti‐seizure medications on exposure to statins: A systematic review and meta‐analysis
Abstract Objectives Antiseizure medications (ASMs) can reduce the efficacy of statin treatment, partly due to reduction in statin concentrations. In this systematic review and network meta‐analysis (NMA), we compared the effects of ASMs and the prototypical enzyme inducer rifampin on statin exposure.
Sharon Valiyev Huino +5 more
wiley +1 more source
Oligogenic inheritance in epilepsy: A systematic exome‐wide analysis
Abstract Objective Genetic factors contribute to the majority of epilepsies, but the exact genetic cause remains unknown in most patients. Incomplete penetrance and variable expressivity are frequent, and recent studies showed a burden of deleterious variants in epilepsy genes, suggesting a role for oligogenic inheritance.
Sarah Duerinckx +192 more
wiley +1 more source
Abstract Objective A multi‐electrode array (MEA) is a powerful extracellular recording technique for long‐term monitoring of neuronal network activity. In recent years, MEA‐based assays have been applied increasingly to evaluate drug efficacy and neurotoxicity, including the assessment of anti‐seizure medications (ASMs). However, systematic comparisons
Griselda Marku +4 more
wiley +1 more source
Change in clobazam pharmacokinetics after introduction of cenobamate
Abstract Cenobamate is a new antiseizure medication with an unusually high seizure‐free rate, resulting in frequent use in patients with drug‐resistant epilepsy. Many of these patients are taking clobazam (CLB) at baseline. Cenobamate has important interactions with CLB, requiring CLB dose adjustment in conjunction with cenobamate titration.
Melissa R. Osborn +2 more
wiley +1 more source
Long‐term efficacy and safety of adjunctive cenobamate in a multinational Asian population. Open‐label extension (OLE) efficacy population included all patients who had taken ≥1 dose of study drug and had any seizure data during the OLE maintenance phase.
Sang Kun Lee +20 more
wiley +1 more source
Epilepsy is a common and disabling neurological disorder. To significantly improve the quality of life of patients, the primary goal is to achieve seizure freedom.
Antoine Plaquevent +2 more
doaj +1 more source

